Catalyst Event
ABL Bio Inc (298380) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/17/2026, 12:00:00 AM
U.S. FDA agreement on accelerated approval pathway for Givastomig (ABL111) on March 17, 2026. Accelerated pathways significantly shorten time-to-market, likely causing a high positive impact, scheduled.
Korean Translation
미국 FDA와의 지바스토믹 가속 승인 경로 합의 결과가 2026년 3월 17일 발표될 예정됨. 상업화 기간 단축 기대감으로 높은 수준의 긍정적 영향이 예상됨.
Related Recent Events
GC Cell Corporation (144510) · Earnings Release
The company reported a significant net loss for the full year 2025, primarily driven by a large-scale goodwill impairment of approximately KRW 220 billion related to the 2021 merger of its predecessor companies; 10% or more price impact expected.
3/24/2026, 12:00:00 AM
ABL Bio Inc (298380) · Other
ABL Bio Inc. to be added to the FTSE All-World Index on March 23, 2026. Index inclusion typically drives institutional buying, likely resulting in a low price impact, scheduled.
3/23/2026, 12:00:00 AM
ABL Bio Inc (298380) · Other
Reorganization of R&D division to establish independent 'ADC Technology' and 'Antibody Discovery' teams on March 22, 2026. Strategic focus on high-growth ADC sector is expected to have a medium positive impact, scheduled.
3/22/2026, 12:00:00 AM
Yuhan Corp (000100) · Other
The 103rd Annual General Meeting was held on 2026-03-20. Key resolutions included the approval of financial statements for fiscal year 2025 and the confirmation of a dividend of 600 KRW per common share.
3/20/2026, 12:00:00 AM
ABL Bio Inc (298380) · Other
Announcement of preclinical data presentation for ABL206 and ABL209 at AACR on March 19, 2026. Positive data at major conferences often boosts biotech valuations, estimated as a medium impact, scheduled.
3/19/2026, 12:00:00 AM